Interim Analysis of a Post-authorisation Safety Study on the Long-Term Safety of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients with Primary Immunodeficiency Diseases in Europe

被引：0
|
作者：
Ellerbroek, P. M. [1 ]
Van Paassen, P. [2 ]
Hanitsch, L. [3 ]
Plebani, A. [4 ,5 ]
Schmidt, R. E. [6 ]
Van Hagen, P. M. [7 ]
Wang, P. [8 ]
Fielhauers, K. [9 ]
Leibls, H. [9 ]
Chavan, S. [8 ]
Yel, L. [10 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands
[2] Acad Ziekenhuis Maastricht, Maastricht, Netherlands
[3] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany
[4] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy
[5] ASST Spedali Civili Brescia, Brescia, Italy
[6] Hannover Med Sch, Klin Immunol & Rheumatol, Hannover, Germany
[7] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands
[8] Shire US Inc, Lexington, MA USA
[9] Baxalta Innovat GmbH, Vienna, Austria
[10] Baxalta US Inc, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR2226
引用
收藏
页码：402 / 403
页数：2
相关论文
共 50 条
  • [21] Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study
    Rubinstein, Arye
    Mabudian, Mohsen
    Mcneil, Donald
    Patel, Niraj C.
    Wasserman, Richard L.
    Gupta, Sudhir
    Carrasco, Paz
    Chen, Jie
    Garcia, Enrique
    Nagy, Andras
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (08)
  • [22] Real-World Safety and Tolerability of Facilitated Subcutaneous Immunoglobulin in Pediatric Patients with Primary Immunodeficiency Diseases: Interim Analysis from a Post-authorization Study in Europe
    Ciznar, Peter
    Roderick, Marion
    Schneiderova, Helena
    Jesenak, Milos
    Krivan, Gergely
    Brodszki, Nicholas
    Jolles, Stephen
    Fielhauer, Katharina
    Saeed-Khawaja, Shumyla
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S97 - S98
  • [23] Facilitated subcutaneous immunoglobulin 10% for CIDP: interim results from a long-term safety and tolerability study
    Hadden, R.
    Andersen, H.
    Bril, V.
    Basta, I.
    Rejdak, K.
    Djordjevic, G.
    Greco, E.
    Hasan, S.
    French, J.
    Yel, L.
    Ay, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 286 - 286
  • [24] Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design
    LWasserman, Richard
    Leavis, Helen
    Nagy, Andras
    Carrasco, Paz
    Anderson-Smits, Colin
    McCoy, Barbara
    Bauer, Alexander
    Chu, Liang-Hui
    Freedman, Immanuel
    Li, Zhaoyang
    CLINICAL IMMUNOLOGY, 2024, 262
  • [25] Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
    Zhaoyang Li
    Kristin Follman
    Ed Freshwater
    Frank Engler
    Leman Yel
    Journal of Clinical Immunology, 2023, 43 : 2127 - 2135
  • [26] Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
    Li, Zhaoyang
    Follman, Kristin
    Freshwater, Ed
    Engler, Frank
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (08) : 2127 - 2135
  • [27] Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study
    Borte, Michael
    Raffac, Stefan
    Hrubisko, Martin
    Jahnz-Rozyk, Karina
    Garcia, Enrique
    McCoy, Barbara
    Chavan, Shailesh
    Nagy, Andras
    Yel, Leman
    IMMUNOTHERAPY, 2022, 14 (08) : 609 - 616
  • [28] Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G in Patients Aged ≥18 Years with Primary Immunodeficiency Diseases
    Wasserman, Richard L.
    Stein, Mark
    Kobrynski, Lisa
    Gupta, Sudhir
    Grant, J. Andrew
    Rubinstein, Arye
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S53 - S53
  • [29] INTERIM RESULTS OF A NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) ON THE LONG-TERM SAFETY OF SCIG 10% INFUSION FACILITATED WITH RECOMBINANT HUMAN HYALURONIDASE (rHUPH20) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) IN EUROPE (EU)
    Ellerbroek, Pauline
    Hanitsch, Leif
    Schmidt, Reinhold
    van Hagen, P. M.
    van Paassen, Pieter
    Borte, Michael
    Berner, Todd
    Nikolov, Nikolai
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 216 - 216
  • [30] LONG-TERM SAFETY, EFFICACY, AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN G IN PEDIATRIC PATIENTS AGED <16 YEARS WITH PRIMARY IMMUNODEFICIENCIES
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Kobrynski, L.
    Puck, J.
    Gupta, S.
    Engl, W.
    McCoy, B.
    Leibl, H.
    Yel, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A34 - A34
12345